3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Advanced Solid Tumours
5
Ovarian Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Previously Treated Non Small Cell Lung Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
1
Muscle Invasive Bladder Cancer
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Advanced Solid Tumors
1
Interventions
vistusertib
1
tislelizumab
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Muscle Invasive Bladder Cancer
×
adavosertib
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled